Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.68 |
| ▸ | TACR3 | P29371 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.64 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970873 | 0.93 | MOK (0.80) | HTTMOKTP53TACR3MEN1 | |
| SCHEMBL16099320 | 0.89 | HTT (0.61) | HTTMOKTP53TACR3MEN1 | |
| SCHEMBL23722895 | 0.89 | TP53 (0.66) | HTTMOKTP53TACR3MEN1 | |
| Hydrochloric Acid SCHEMBL16098467 | 0.88 | HTT (0.60) | HTTMOKTP53TACR3MEN1 | |
| SCHEMBL23722859 | 0.86 | TACR3 (0.67) | MOKTP53TACR3MEN1CACNA1B | |
| SCHEMBL23722878 | 0.85 | MOK (0.76) | HTTMOKTP53TACR3MEN1 | |
| SCHEMBL23722857 | 0.85 | MAPT (0.81) | HTTTP53MEN1CACNA1BAPBA1 | |
| SCHEMBL23722840 | 0.84 | TACR3 (0.69) | HTTTP53TACR3MEN1CACNA1B | |
| SCHEMBL23722876 | 0.84 | KDM4E (0.72) | HTTMOKTP53TACR3MEN1 | |
| SCHEMBL23722846 | 0.83 | TACR3 (0.70) | HTTMOKTP53TACR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | AR, KLK3, BRDT | HTT 2642/4885MOK 4545/4885TP53 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.